Cargando…

Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study

PURPOSE: To characterize the pharmacokinetics (PK) of, and perform an exploratory exposure–response (E–R) analysis for, pertuzumab in patients with HER2-positive early breast cancer (EBC) within the APHINITY study (NCT01358877, BIG 4–11/BO25126/TOC4939G). METHODS: A previously developed pertuzumab t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kirschbrown, Whitney P., Kågedal, Matts, Wang, Bei, Lindbom, Lars, Knott, Adam, Mack, Rachelle, Monemi, Sharareh, Nijem, Ihsan, Girish, Sandhya, Freeman, Christie, Fumagalli, Debora, McConnell, Robin, Jerusalem, Guy, Twelves, Chris, Baselga, José, von Minckwitz, Gunter, Bines, José, Garg, Amit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499763/ https://www.ncbi.nlm.nih.gov/pubmed/30976844 http://dx.doi.org/10.1007/s00280-019-03826-1

Ejemplares similares

Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study
por: Kirschbrown, Whitney P., et al.
Publicado: (2018)

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial
por: de Azambuja, E., et al.
Publicado: (2023)

Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial
por: Franzoi, Maria Alice, et al.
Publicado: (2022)

Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer
por: Kirschbrown, Whitney P., et al.
Publicado: (2019)

Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
por: Wang, Bei, et al.
Publicado: (2021)

Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics
por: Liu, Stephanie N., et al.
Publicado: (2021)

Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer
por: Quartino, Angelica L., et al.
Publicado: (2017)

Corrections to “Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab”
por: Lenihan, D., et al.
Publicado: (2019)

Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism
por: Fuentes, Gloria, et al.
Publicado: (2011)

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)
por: Miles, David, et al.
Publicado: (2013)

A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics
por: Yu, Jiajie, et al.
Publicado: (2020)

Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study
por: Lin, Nancy U., et al.
Publicado: (2021)

Pertuzumab in Metastatic Breast Cancer
por: Patel, Rachana, et al.
Publicado: (2012)

Analysis of Longitudinal‐Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric Models
por: Lu, Tong, et al.
Publicado: (2020)

Rifaximin for Pertuzumab-Related GI Toxicities
por: Soyano, Aixa E., et al.
Publicado: (2017)

Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab
por: Hughes, Juliana Bentes, et al.
Publicado: (2012)

Time‐to‐Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine‐Citrulline‐Monomethylauristatin E Antibody–Drug Conjugates
por: Kågedal, Matts, et al.
Publicado: (2019)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
por: Bianchini, Giampaolo, et al.
Publicado: (2017)

Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates
por: Li, Chunze, et al.
Publicado: (2020)

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2(+) breast cancer in the adaptively randomized I-SPY2 trial
por: Clark, Amy S., et al.
Publicado: (2021)

Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain †
por: Cruz, Victor L., et al.
Publicado: (2023)

Evaluation of (89)Zr-pertuzumab in Breast Cancer Xenografts
por: Marquez, Bernadette V., et al.
Publicado: (2014)

Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties
por: Luo, Cheng, et al.
Publicado: (2017)

Safety and efficacy evaluation of pertuzumab in patients with solid tumors
por: Zhu, Chenjing, et al.
Publicado: (2017)

Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab
por: Mortimer, Joanne E., et al.
Publicado: (2019)

Exposure–response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters
por: Garg, Amit, et al.
Publicado: (2013)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
por: Vieira, Cláudia, et al.
Publicado: (2022)

Intrinsic and Extrinsic Pharmacokinetic Variability of Small Molecule Targeted Cancer Therapy
por: Reyner, Eric, et al.
Publicado: (2019)

A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score
por: Moein, Anita, et al.
Publicado: (2023)

Precision medicine and personalized breast cancer: combination pertuzumab therapy
por: Reynolds, Kerry, et al.
Publicado: (2014)

Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy
por: Mortimer, Joanne, et al.
Publicado: (2014)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

A Rare Case of Pertuzumab-Induced Toxic Epidermal Necrolysis
por: Mohamed Jiffry, Mohamed Zakee, et al.
Publicado: (2023)

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
por: Dang, Chau, et al.
Publicado: (2022)

Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data Sources
por: Monemi, Sharareh, et al.
Publicado: (2016)

Autoradiographic Mapping of 5-H T (1B/1D) Binding Sites in the Rhesus Monkey Brain Using [carbonyl-(11)C]zolmitriptan
por: Lindhe, Örjan, et al.
Publicado: (2011)

A longitudinal model for the Mayo Clinical Score and its sub-components in patients with ulcerative colitis
por: Kawakatsu, Sonoko, et al.
Publicado: (2021)

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
por: Sims, A H, et al.
Publicado: (2012)

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
por: El-Sahwi, K, et al.
Publicado: (2010)

The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
por: Moya-Horno, I, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8na9cp6pu970fg0jtmtdb3ki8a